China National Accord Medicines Corporation (000028) Fair Value & Analysis

Healthcare · CN · Market cap 12.7B CNY

Analysis

China National Accord Medicines Corporation (000028) currently trades at ¥22.55, while our model-based Fair Value estimate is ¥51.50 — implying the stock looks roughly 128.4% undervalued today. We read business quality at 86/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

China National Accord Medicines Corporation Ltd. engages in the retail and distribution of pharmaceutical products in China and internationally. The company offers new and special drugs and medications for chronic diseases. It also provides traditional Chinese medicine, Western medicine, rehabilitation therapy, and various medical-related resources, as well as chemical drugs, OTC drugs, and health products. The company was formerly known as Shenzhen Health Mineral Water Corp., Ltd. China National Accord Medicines Corporation Ltd. was incorporated in 1993 and is headquartered in Shenzhen, China. China National Accord Medicines Corporation Ltd. operates as a subsidiary of Sinopharm Group Co., Ltd.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.